Grace M. Ahimbisibwe
Kampala, C, Uganda
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Dolutegravir as First- or Second-line Treatment for Children With HIV: 240-Week Follow-up of the ODYSSEY Randomized Trial.
Journal: Open forum infectious diseases
Published: January 26, 2026
Predictors of Treatment Failure in Children With HIV Starting First-line Antiretroviral Therapy in the ODYSSEY Trial.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: October 16, 2025
Predictors of treatment failure in children living with HIV starting first-line antiretroviral therapy in the ODYSSEY trial.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: October 16, 2025
Weight gain, body composition, and metabolic parameters of dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: an ancillary analysis of the ODYSSEY trial.
Journal: The Lancet. Child & adolescent health
Published: August 28, 2025
Challenges towards an AIDS-free generation in Africa and Asia.
Journal: Current opinion in HIV and AIDS
Published: August 15, 2024
Virological outcomes and genotypic resistance on dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial.
Journal: The lancet. HIV
Published: November 07, 2023
Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial.
Journal: The Lancet. Child & adolescent health
Published: March 06, 2023
Effect of dolutegravir on folate, vitamin B12 and mean corpuscular volume levels among children and adolescents with HIV: a sub-study of the ODYSSEY randomized controlled trial.
Journal: Journal of the International AIDS Society
Published: November 13, 2022
Viral load suppression after intensive adherence counselling among adult people living with HIV at Kiswa health centre, Kampala: a retrospective cohort study. Secondary data analysis.
Journal: AIDS research and therapy
Published: September 12, 2022
Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial.
Journal: The lancet. HIV
Published: March 03, 2022
Showing 1-11 of 11
Last Updated: 09/26/2026